America’s biopharmaceutical research companies invested a record $67.4 billion last year in the research and development of new medicines and vaccines – an increase of $1.5 billion from 2009, according to analyses by the PhRMA and Burrill & Company.
PhRMA member companies alone spent an estimated $49.4 billion on biopharmaceutical R&D last year, a 6.5 percent increase over 2009, according to the PhRMA survey. The Burrill & Company analysis shows that additional biopharmaceutical research companies in the United States spent an estimated $18.0 billion on R&D in 2009.
More than 75 percent of research dollars were invested in the U.S.
Over the past decade, biopharmaceutical companies have consistently invested around 19 percent of domestic sales on R&D activities; in 2010, that figure jumped to 20.5 percent.
